Metabolism-dependent mutagenicity of a compound containing a piperazinyl indazole motif: Role of a novel P450-mediated metabolic reaction involving a putative oxaziridine intermediate

被引:12
作者
Chen, Hao [1 ]
Murray, Joel
Kornberg, Brian
Dethloff, Lloyd
Rock, David
Nikam, Sham
Mutlib, Abdul E.
机构
[1] Pfizer Global Res & Dev, Dept Pharmacokinet Dynam & Metab, Ann Arbor, MI 48105 USA
[2] Pfizer Global Res & Dev, Dept World Wide Safety Sci, Ann Arbor, MI 48105 USA
[3] Pfizer Global Res & Dev, Dept Med Chem, Ann Arbor, MI 48105 USA
[4] Pfizer Global Res & Dev, Dept Pharmacol, Ann Arbor, MI 48105 USA
关键词
D O I
10.1021/tx050354+
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Compound 1a (6-chloro-5-{3-[4-(1H-indazol-3-yl)-piperazin-1-yl]-propyl}-3,3-dimethyl-1,3-dihydroindol2-one) was mutagenic to Salmonella typhimurium TA98 in the presence of rat liver S9 subcellular fraction. The metabolism of 1a in rat liver S9 or microsomes demonstrated that it underwent a P450-mediated N-deindazolation (loss of indazole ring) as a predominant metabolic pathway. To investigate a possible link between metabolism and mutagenicity, a structural analogue 1b (6-chloro-5-{3-[4-(1Hindazol3-yl)-piperidin-1-yl]-propyl}-3,3-dimethyl-1,3-dihydro-indol-2-one), the cleaved product 2a (6chloro-3,3-dimethyl-5-(3-piperazin-1-yl-propyl)-1,3-dihydro-indol-2-one), and the core motif 3a (3piperazinyl indazole) were evaluated in the Ames assay. It was found that 1b was not mutagenic to Salmonella typhimurium TA98 in the absence or presence of a metabolic activating system. In contrast to 1a, 1b did not undergo the metabolic cleavage (loss of indazole ring). Marginal mutagenicity of 2a to TA98 was observed with rat liver S9, whereas 3a was shown to be a promutagen. It was further demonstrated that 1a inactivated P450 3A, the principle enzyme catalyzing the N-deindazolation reaction, in an NADPH- ,time-, and concentration- dependent manner. The kinetics of inactivation was characterized by a K-I of 8.1 mu M and k(inact) of 0.114 min(-1). The differences in mutagenicity between 1a and 1b suggest that a chemical bond extending from the 3- position of the indazole to a heteroatom ( as part of another cyclic ring) is a prerequisite for the toxicity. The metabolic process leading to the elimination of the indazole from the rest of the molecule apparently plays a key role in causing mutagenicity. It is postulated that the N-deindazolation of 1a proceeds Via an oxaziridine intermediate, the formation of which is indirectly inferred from the presence of benzoic acid in microsomal incubations. Benzoic acid is thought to be derived from the hydrolysis of 3-indazolone, an unstable product generated from the oxaziridine. Evidence suggests that the electrophilic oxaziridine intermediate may be responsible for the mutagenicity and inactivation of P450 3A.
引用
收藏
页码:1341 / 1350
页数:10
相关论文
共 23 条
[11]   PURIFICATION AND CHARACTERIZATION OF LIVER MICROSOMAL CYTOCHROMES-P-450 - ELECTROPHORETIC, SPECTRAL, CATALYTIC, AND IMMUNOCHEMICAL PROPERTIES AND INDUCIBILITY OF 8 ISOZYMES ISOLATED FROM RATS TREATED WITH PHENOBARBITAL OR BETA-NAPHTHOFLAVONE [J].
GUENGERICH, FP ;
DANNAN, GA ;
WRIGHT, ST ;
MARTIN, MV ;
KAMINSKY, LS .
BIOCHEMISTRY, 1982, 21 (23) :6019-6030
[12]   MECHANISM-BASED INACTIVATION OF HUMAN LIVER MICROSOMAL CYTOCHROME-P-450-IIIA4 BY GESTODENE [J].
GUENGERICH, FP .
CHEMICAL RESEARCH IN TOXICOLOGY, 1990, 3 (04) :363-371
[13]   Atypical kinetic profiles in drug metabolism reactions [J].
Hutzler, JM ;
Tracy, TS .
DRUG METABOLISM AND DISPOSITION, 2002, 30 (04) :355-362
[14]   Quantitative analysis of eight testosterone metabolites using column switching and liquid chromatography tandem mass spectrometry [J].
Magnusson, MO ;
Sandström, R .
RAPID COMMUNICATIONS IN MASS SPECTROMETRY, 2004, 18 (10) :1089-1094
[15]  
MAJESKA JB, 2000, 31 ANN M ENV MUT SOC
[16]   REVISED METHODS FOR THE SALMONELLA MUTAGENICITY TEST [J].
MARON, DM ;
AMES, BN .
MUTATION RESEARCH, 1983, 113 (3-4) :173-215
[17]   P450 IN THE RAT AND MAN - METHODS OF INVESTIGATION, SUBSTRATE SPECIFICITIES AND RELEVANCE TO CANCER [J].
NEDELCHEVA, V ;
GUT, I .
XENOBIOTICA, 1994, 24 (12) :1151-1175
[18]  
Prakash C, 1997, DRUG METAB DISPOS, V25, P897
[19]  
SILVERMAN RB, 1996, SEL METH EN, P291
[20]   Polymorphic variants (CYP2C9*3 and CYP2C9*5) and the F114L active site mutation of CYP2C9: Effect on atypical, kinetic metabolism profiles [J].
Tracy, TS ;
Hutzler, JM ;
Haining, RL ;
Rettie, AI ;
Hummel, MA ;
Dickman, LJ .
DRUG METABOLISM AND DISPOSITION, 2002, 30 (04) :385-390